JNJ-64619178

SKU: orb1308171

Description

JNJ-64619178 is a potent, orally bioavailable, and pseudo-irreversible PRMT5 inhibitor with an IC50 of 0.14 nM. It demonstrates promising anti-tumor efficacy in both in vitro and in vivo models of lung cancer, making it a valuable tool for oncology research.

Research Area

Epigenetics & Chromatin

Key Properties

• CAS Number: 2086772-26-9
• MW: 483.36
• Purity: 99.98% (May vary between batches)
• Formula: C₂₂H₂₃BrN₆O₂
• SMILES: Nc1nc2cc(CC[C@H]3C[C@H]([C@H](O)[C@@H]3O)n3ccc4c(N)ncnc34)ccc2cc1Br
• Target: Histone Methyltransferase
• Solubility: DMSO:120 mg/mL (248.26 mM);10% DMSO+40% PEG300+5% Tween-80+45% Saline:3.3 mg/mL (6.83 mM)

Bioactivity

• Target IC50:
  PRMT5:0.14 nM
• In Vivo:
  In several non-small cell lung cancer and small cell lung cancer mouse xenograft models, JNJ-64619178 (p.o.) causes efficient inhibition of dimethylation of SMD1/3 proteins, components of the splicing machinery and direct substrates of the methylosome .
  Read more...
• In Vitro:
  JNJ-64619178 displays effective and broad inhibition of cellular growth. JNJ-64619178 binds simultaneously to the S-adenosylmethionine (SAM)- and protein substrate- binding pockets of the PRMT5/MEP50 complex with a pseudo-irreversible mode-of-action .
  Read more...

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

HistoneMethyltransferase, Histone Methyltransferase, Inhibitor, JNJ64619178, JNJ-64619178, JNJ 64619178, inhibit, Onametostat, PRMT5

Compound Identifiers

PubChem CID

126637809